News

20.09.23 FDA Grants US Orphan Drug Designation to Medannex’s First-in-Class Therapy MDX-124
21.08.23 Medannex Announces First Patient Treated in Phase 1b Clinical Study of Groundbreaking Anti-Annexin-A1 Therapy
24.04.23 Medannex’s First-in-class Therapy Awarded UK ‘Innovation Passport’ to Accelerate Time to Market
01.03.23 MDX-124 receives Orphan Designation from the EMA for the Treatment of Pancreatic Cancer
03.01.23 Medannex features in global pharmaceutical publication ‘Scrip’
12.12.22 Regulators give green light to first-in-human study with MDX-124
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5